SII lowers each dose of Covovax jab from Rs 900 to Rs 225 excluding taxes

A day after its Covid shot Covovax was included on the CoWIN portal for inoculation of children aged 12-17 years at private vaccination centres, the Serum Institute of India (SII) on Tuesday reduced the price of each dose of the vaccine from Rs 900 to Rs 225, excluding taxes.

Topics
Coronavirus | Serum Institute of India | Coronavirus Vaccine

Press Trust of India  |  New Delhi 

A day after its Covid shot Covovax was included on the CoWIN portal for inoculation of children aged 12-17 years at private vaccination centres, the (SII) on Tuesday reduced the price of each dose of the vaccine from Rs 900 to Rs 225, excluding taxes.

Following recommendation of the National Technical Advisory Group on Immunisation (NTAGI) the provision of the vaccine option was included on the portal on Monday.

On Tuesday, Director for Government and Regulatory Affairs, SII, Prakash Kumar Singh, is learnt to have communicated to the government that the firm is reducing the price of each dose from Rs 900 to Rs 225 plus goods and services tax (GST) for private hospitals. In addition, a private hospital can charge up to Rs 150 as service charge.

The price of the vaccine, Covovax, is learnt to have been revised on the CoWIN portal.

India's drug regulator had approved Covovax for restricted use in emergency situations in adults on December 28 last year and in the 12-17 age group, subject to certain conditions, on March 9.

Currently, children aged 12 to 14 years are vaccinated with Biological E's Corbevax, while those in the 15-18 age group are being administered Bharat Biotech's Covaxin free of cost at government vaccination centres.

At private centres a dose of Covaxin costs Rs 386, including GST, while Corbevax costs Rs 990.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Read our full coverage on Coronavirus
First Published: Tue, May 03 2022. 23:10 IST
RECOMMENDED FOR YOU